Qtern will be released in Korea after 4 years of approval

Onglyza+ Forxiga

Generic development is also active.

The DPP-4 inhibitor and SGLT-2 inhibitor diabetes complex Qtern will be released four years after approval in Korea.

 

According to related industries, AstraZeneca Korea will start promotional activities for Qtern, a product that combines Onglyza and Forxiga, on the 1st of next month (November).

 

Qtern was approved in Korea in March 2017, but its launch in Korea was delayed as the problem of insurance benefits for diabetes combined therapy was not resolved.

 

However, a change in the market is expected as insurance authorities have recently discussed recognizing the combined benefits of SGLT-2 inhibitors.

 

A meeting of diabetes experts convened by the HIRA integrated the benefits of a combination of DPP-4 inhibitors and SGLT-inhibitors.

 

The reason for the decision to release Qtern is also believed to have reflected this.

 

Currently, in addition to Qtern, combinations of DPP-4 inhibitors and SGLT-2 inhibitors are licensed in Korea, Beringer Ingelheim's Esglito and MSD's Sitagliptin+Ertugliflozin.

 

It has been confirmed that they are also preparing to launch as the benefit issue has been resolved.

 

On the 25th, GC Pharma's GC2123A received approval from the MFDS for a biological equivalence test plan.

 

The active ingredient of this product candidate is known as the same ingredient drug Empagliflozin+Linagliptin.

 

In addition, Dongkoo Bio applied for permission for a combination drug of Januvia (Sitagliptin) and Forxiga in March.

 

LG Chem is conducting commercialization clinical trials for Zemiglo and SGLT-2 inhibitors, while Aju is conducting commercialization clinical trials for a combination drug of Jardiance and Forxiga.

 

Meanwhile, the PMS period of the DPP-4 inhibitor and SGLT-2 inhibitor combination is now less than two years away.

 

The PMS period ends in March 2023.

 

Since March 2023, news of generic development has continued as it is possible to apply for a generic license.